Etavopivat for Sickle Cell Disease

"The minimum age for eligibility in this medical trial is 12, whereas the upper limit of participation has been set at 21."

"The safety of etavopivat was assessed by our team at Power and scored a 2. As this is only in its second phase, there is some research that supports the drug's security but not yet any evidence to verify efficacy."

"Data hosted on clinicaltrials.gov reveals that the recruitment period for this investigation has expired, last edited on February 10th 2023. Despite this trial not being open to new participants, there are an abundance of other trials with 188 studies accepting applicants currently."

"In order to be considered for this trial, a potential participant must have been diagnosed with sickle cell disease and lie in the 12-21 age range. In total, around a dozen patients are being admitted into the experiment."

"Forma Therapeutics, Inc., the clinical trial sponsor, has reported that their primary outcome will be measuring effect of etavopivat on oxygen ejection fraction (OEF) over a 24-week time frame. Secondary outcomes include: examining correlation between OEF and change in Hb levels; exploring connection between cerebral metabolic rate of oxygen (CMRO2) and alteration in Hb levels; as well as evaluation of adverse events experienced by participants with SCD. Finally, they aim to furnish tabulated information regarding deaths attributed to TEAEs or drug discontinuation caused by these events."